Abbott wraps up patient enrollment in Absorb device studies

04/11/2014 | (Boston)

Abbott has finished enrolling some 2,800 patients in three clinical trials evaluating its Absorb system, a dissolving, drug-eluting scaffold intended to treat patients with heart vessel blockage. The trials, being conducted in the U.S., Japan and China, are meant to back the company's regulatory approval applications for the device in the three countries.

View Full Article in: (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX